SCHEMBL23354547

SCHEMBL23354547

Cc1ccc(-c2ccccc2C(=O)O)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 3/20 0.53
CHRM2 P08172 1/20 0.53
CHRM4 P08173 1/20 0.53
CHRM5 P08912 1/20 0.53
CHRM1 P11229 1/20 0.53
CHRM3 P20309 1/20 0.53
MCL1 Q07820 1/20 0.53
MYC P01106 1/20 0.51
KMO O15229 2/20 0.51
KDM4E B2RXH2 1/20 0.50
EIF4E P06730 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LDHA P00338 1/20 0.46
PTPN11 Q06124 1/20 0.46
P2RX7 Q99572 1/20 0.45
AKR1C2 P52895 2/20 0.45
AKR1C1 Q04828 2/20 0.45
PDK2 Q15119 1/20 0.45
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3542609 0.85 PTGER1 (0.56) CHRM1EIF4EALDH1A1P2RX7AKR1C2
SCHEMBL269897 0.85 MCL1 (0.57) MCL1MYCKDM4EALDH1A1LDHA
SCHEMBL20099761 0.83 ALPL (0.46) FTOCHRM2CHRM4CHRM5CHRM1
SCHEMBL4881566 0.81 ALDH1A1 (0.58) MCL1KDM4EEIF4EALDH1A1PTPN11
SCHEMBL31161066 0.81 CHRM1 (0.53) FTOCHRM1KMOEIF4EALDH1A1
SCHEMBL17796995 0.81 ACMSD (0.53) MCL1MYCKMOKDM4EALDH1A1
SCHEMBL10024259 0.81 MCL1 (0.56) FTOMCL1EIF4EALDH1A1AKR1C2
SCHEMBL4911989 0.79 TSHR (0.51) KDM4EALDH1A1PTPN11PDK2TSHR
SCHEMBL4898752 0.79 NOTUM (0.66) ALDH1A1
SCHEMBL5103351 0.78 ERN1 (0.58) MCL1MYCKMOKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 US disclosed
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-3822268-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2021-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 FTO 2839/4885CHRM2 996/4885CHRM4 1377/4885
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 FTO 2839/4885CHRM2 996/4885CHRM4 1377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.